This company uses AI to decipher complex immune system data, generating generalizable patterns from individual patient responses. Their platform aids in drug discovery by identifying new targets, developing vaccines, and discovering therapeutic antibodies. They also offer response prediction and biomarker development services for oncology and autoimmune diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for diagnosing and treating complex diseases often lack the ability to fully leverage the intricate data contained within the immune system. This limitation hinders early and accurate disease detection, as well as the development of targeted and effective therapies.
Solution
MyImmune offers an AI-powered platform that decodes the adaptive immune system by analyzing B-cell receptor (BCR) and T-cell receptor (TCR) repertoire data. The platform transforms complex biological data into actionable insights, accelerating the discovery of novel diagnostics and therapeutics. By leveraging adaptive immune network analysis, MyImmune enables highly accurate detection of diseases, including cancer, autoimmune disorders, and infectious diseases. The platform also identifies therapeutic immune cells in healthy individuals, opening new avenues for precision diagnostics and treatment.
Target Audience
MyImmune's primary target audience includes researchers and pharmaceutical companies focused on developing advanced diagnostics and targeted therapies for complex diseases.
Features
- AI-driven analysis of BCR and TCR repertoire data
- Novel clustering method based on CDR sequences for antibody identification
- Identification of antigen-specific and neutralizing antibodies
- Detection of cancer, autoimmune, and infectious diseases through adaptive immune receptor paratope networks
- Identification of therapeutic immune cells in healthy individuals